



First participant enrolled in Swisse Krill Oil clinical trial

Media Release
8 May 2018

Swisse Wellness today announced that the first participant is enrolled into a new randomised, double-blind, placebo-controlled study to investigate the effect on knee pain and the safety of Swisse High Strength Deep Sea Krill Oil (Superba BOOST) in adults with mild-to-moderate Osteoarthritis of the knee.

Osteoarthritis is the most common form of arthritis in Australia affecting almost 2.2 million Australians (9% of the population), according to the Australian Bureau of Statistics (ABS) 2014–15 National Health Survey. Healthcare costs for Osteoarthritis were estimated to be over \$2.1 billion in 2015¹.

Swisse Managing Director, Oliver Horn, says Osteoarthritis is a leading cause of pain and disability worldwide and this is one of the factors driving the growing krill oil market. "This trial signifies the commitment Swisse has to continually growing the science behind our products."

Conducted across multiple study sites in Australia, this study will enrol a total of 238 participants with osteoarthritis of the knee and will measure symptoms associated with the condition.

The clinical trial is being conducted in collaboration with Aker BioMarine and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and is the second clinical trial under the Swisse Wellness and CSIRO strategic Research Agreement signed in 2016.

NB: Swisse Wellness publishes all research and scientific references on its website www.swisse.com.au

For media enquiries, contact Swisse Wellness:

Reuben Aitchison
Senior Communications Manager
Reuben.Aitchison@hh.global / +61 3 9418 675

Abbey Thomas
PR Manager
Abbey.Thomas@hh.global / +61 3 9427 6935

¹ Ackerman IN, Pratt C, Gorelik A, Liew D (2017). The projected burden of osteoarthritis and rheumatoid arthritis in Australia: A population-level analysis. *Arthritis Care Res (Hoboken)*. 2017 Sep 12. doi: 10.1002/acr.23414